14 enrolling by invitation. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Enrolling by invitation 14 |
| Phase 2 | 6 | Enrolling by invitation 6 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Characterization of Doxycycline Pharmacokinetics and Adherence Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group - Sexually Transmitted Infection | Phase 1 | Enrolling by invitation | HIV Prevention Trials Network | 16 | 2026-08-27 | 2026-09-17 |
| A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) Recombinant Herpes Zoster Vaccine, adjuvant placebo, Placebo - Herpes | Phase 1 | Enrolling by invitation | Changchun BCHT Biotechnology Co. | 120 | 2026-05-28 | 2026-06-08 |
| Racecadotril for Organ Injury in Sepsis Patients Racecadotril, Water (Placebo) - Sepsis | Phase 1 / Phase 2 | Enrolling by invitation | Zhujiang Hospital | 44 | 2026-05-06 | 2026-05-28 |
| Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza A/Mallard/Ohio-99/MM4/1989 H10N7 - Influenza Infection, Infections | Phase 1 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 33 | 2026-04-21 | 2026-10-15 |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine - Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection | Phase 1 | Enrolling by invitation | Vancouver Coastal Health | 1 | 2026-01-11 | 2026-06-03 |
| A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort - Genital Herpes | Phase 1 | Enrolling by invitation | Changchun BCHT Biotechnology Co. | 144 | 2025-10-13 | 2026-01-09 |
| Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART Analytical Treatment Interruption - HIV | Phase 1 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2025-09-08 | 2026-10-01 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection, Human Tetanus Immunoglobulin, Placebo - Tetanus | Phase 1 | Enrolling by invitation | Lanzhou Institute of Biological Products Co., Ltd | 68 | 2025-08-18 | 2026-01-28 |
| Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. BioTTT001 injection - Recurrent High-grade Glioma | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 30 | 2024-11-26 | 2026-03-23 |
| A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors BioTTT001 injection - Solid Tumor | Phase 1 | Enrolling by invitation | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 12 | 2024-05-07 | 2025-11-26 |
| Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis Contezolid, Linezolid (LZD) - Tuberculosis, Meningitis | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Chest Hospital | 24 | 2024-02-01 | 2025-02-06 |
| Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis Contezolid, Linezolid (LZD) - Tuberculosis, Bone | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Chest Hospital | 24 | 2024-01-31 | 2025-02-06 |
| Anti-viral T-cell Therapy by Gamma Capture Specific T- Lymphocytes - Adenovirus, Cytomegalovirus Infections | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 25 | 2024-01-08 | 2026-06-29 |
Adenoviridae Infections (3) · Tuberculosis (2) · Agammaglobulinemia (1) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Glioma (1) · HIV Infections (1) · Herpes Genitalis (1) · Herpes Simplex (1) · Immunologic Deficiency Syndromes (1) · Influenza, Human (1) · Lung Diseases (1) · Meningitis (1) · Mycobacterium Infections, Nontuberculous (1)
Virus Diseases (7) · DNA Virus Infections (6) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Gram-Positive Bacterial Infections (4) · Actinomycetales Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Herpesviridae Infections (3) · Mycobacterium Infections (3) · Urogenital Diseases (3) · Immune System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Linezolid (3) · contezolid (2) · Amikacin (1) · Busulfan (1) · Ceftaroline (1) · Cilastatin, Imipenem Drug Combination (1) · Clofazimine (1) · Cohort Studies (1) · Fibroblast Growth Factor 7 (1) · Filgrastim (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Water (1) · bedaquiline (1) · omadacycline (1) · plerixafor (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Beijing Bio-Targeting Therapeutics Technology Co., Ltd (2) · Beijing Chest Hospital (2) · Changchun BCHT Biotechnology Co. (2) · HIV Prevention Trials Network (1) · Lanzhou Institute of Biological Products Co., Ltd (1) · Paul Szabolcs (1) · Vancouver Coastal Health (1) · Zhujiang Hospital (1)
China (8) · United States (5) · Canada (1)
Funan Liu, MD (1) · Jianchang He (1) · Luca T Giurgea, M.D. (1) · Mackenzie Cottrell, PharmD, MS (1) · Mark Marzinke, PhD (1) · Michael C Sneller, M.D. (1) · Paul Szabolcs, MD (1) · Suk S De Ravin, M.D. (1) · Zhanguo Liu, M.D.PhD (1) · Zhenning Wang, MD (1)
UM1AI068619 (1)